-

 

Women: PFAS and Hormone Therapy Interactions - Implications for Women’s Health

Abstract

Per- and polyfluoroalkyl substances (PFAS) have emerged as one of the most concerning groups of environmental contaminants due to their persistence, bioaccumulative nature, and ability to interfere with hormonal systems. As their ubiquity grows—from water sources to household goods—their intersection with hormone therapy (HT) presents a largely overlooked but critical area of concern for women’s health. This paper examines the pathways through which PFAS interact with hormone therapies, the biochemical mechanisms involved, their health consequences, and the social and policy dimensions of exposure. It further highlights the disproportionate burden borne by women in low- and middle-income regions, particularly around contaminated water systems such as Lake Victoria, and proposes an integrated environmental-health policy framework.

1. Introduction

Hormone therapy (HT) remains an essential medical intervention for women experiencing menopause, premature ovarian failure, infertility, and gender-affirming transitions. The therapy relies on the delicate balance and stability of steroid hormones—primarily estrogens and progestogens—whose efficacy depends on precise receptor interactions, stable metabolism, and predictable clearance pathways.

However, environmental contaminants such as PFAS, often termed “forever chemicals,” disrupt this balance by mimicking, inhibiting, or modulating endocrine function. PFAS are used in industrial and consumer products such as non-stick cookware, firefighting foams, waterproof textiles, and cosmetics. Due to their chemical stability, PFAS accumulate in the environment, enter water systems, and ultimately bioaccumulate in human tissue.

For women on HT, this exposure poses a dual risk: (1) direct endocrine disruption that alters natural hormone balance and (2) interference with the pharmacokinetics and pharmacodynamics of therapeutic hormones. Understanding these interactions is essential for developing safe clinical protocols and informed environmental policies.

2. PFAS Exposure Pathways and Biochemical Mechanisms

PFAS enter the human body primarily through drinking water, food, inhalation of contaminated air or dust, and dermal absorption from cosmetics. Once inside the body, PFAS bind to serum proteins such as albumin, accumulate in the liver and kidneys, and persist for years.

Biochemically, PFAS influence hormone systems through:

  • Activation of peroxisome proliferator-activated receptors (PPARs): These regulate genes involved in lipid metabolism and steroid hormone synthesis.

  • Competition with endogenous hormones for estrogen, progesterone, and androgen receptors.

  • Interference with hepatic enzymes (e.g., CYP3A4 and CYP1A2) responsible for metabolizing estrogens and progestogens.

  • Disruption of thyroid and adrenal function, indirectly affecting estrogen and progesterone regulation.

Such disruptions alter the metabolic and biological fate of hormone therapies, leading to reduced efficacy, adverse reactions, or altered risk profiles.

3. PFAS and Women’s Endocrine Function

PFAS are endocrine-disrupting chemicals (EDCs) with well-documented effects on female reproductive and metabolic health.
Key effects include:

  • Reduced estrogen and progesterone levels, leading to menstrual irregularities and shortened reproductive lifespan.

  • Altered follicular development, reducing oocyte quality and fertility.

  • Increased risk of earlier menopause, as observed in multiple cohort studies (e.g., Kim et al., 2021).

  • Impaired thyroid hormone transport, influencing metabolism, mood, and reproductive function.

These disruptions may predispose women to symptoms that mimic or exacerbate menopausal complaints—hot flashes, fatigue, mood swings—leading to increased HT use and yet reduced therapeutic effectiveness due to PFAS interference.

4. PFAS and Hormone Therapy Interactions

4.1 Pharmacokinetic Interference

PFAS alter how hormone therapy drugs are absorbed, metabolized, and cleared. For instance:

  • Estrogens (such as estradiol and ethinylestradiol) are metabolized via hepatic cytochrome P450 enzymes, which PFAS can induce or inhibit. This modifies plasma hormone concentrations and therapeutic response.

  • Progestogens (such as medroxyprogesterone acetate) may undergo faster clearance in PFAS-exposed individuals, reducing protection against endometrial hyperplasia.

  • PFAS may also interfere with sex hormone-binding globulin (SHBG), altering the free-to-bound hormone ratio and the bioavailable fraction of therapeutic hormones.

4.2 Receptor-Level Interference

Experimental evidence suggests that certain PFAS (notably PFOA and PFOS) can bind weakly to estrogen and progesterone receptors, acting as partial agonists or antagonists. This receptor cross-talk blunts the physiological response to HT, particularly in tissues such as bone, cardiovascular endothelium, and the central nervous system.

4.3 Thyroid and Adrenal Axis Crosstalk

Since thyroid function heavily modulates estrogen metabolism and mood, PFAS-induced thyroid impairment can exacerbate menopausal depression, fatigue, and cognitive decline, even in women receiving adequate HT.

5. Health Implications for Women

5.1 Menopausal Symptom Persistence

Women exposed to high PFAS levels may experience persistent vasomotor symptoms (hot flashes, insomnia) despite HT. Altered drug metabolism means that symptom control may require higher or adjusted doses, increasing risk for other complications.

5.2 Reproductive and Fertility Challenges

In fertility treatments, PFAS exposure correlates with lower estradiol responses to ovarian stimulation, reduced embryo implantation rates, and increased miscarriage risk. This interaction complicates hormone-based fertility protocols.

5.3 Cancer and Chronic Disease Risks

Both PFAS and long-term estrogen exposure have been independently linked to breast, ovarian, and endometrial cancers. Their combined effect may amplify oncogenic potential via estrogen receptor activation, oxidative stress, and DNA damage. Additionally, PFAS exposure has been associated with metabolic syndrome, hypertension, and autoimmune diseases, which can worsen under HT if unmonitored.

6. Regional Focus: Women in Africa and the Lake Victoria Context

PFAS contamination has been documented in Lake Victoria, East Africa’s largest freshwater body, due to industrial effluents, urban wastewater discharge, and imported consumer products. Local fish, sediments, and drinking water sources show detectable PFAS levels, posing chronic exposure risks to surrounding communities.

For women in these regions:

  • Waterborne PFAS exposure compounds nutritional, reproductive, and occupational stressors.

  • Women using hormonal contraceptives or menopause therapies may experience reduced efficacy and unexplained hormonal imbalances.

  • PFAS are also found in cosmetics and skin-lightening creams—common in some East African markets—further increasing cumulative exposure.

This intersection of environmental contamination, gendered exposure pathways, and limited healthcare monitoring deepens health inequities. It demonstrates the urgent need for PFAS regulation and integration of environmental exposure screening into reproductive and endocrine healthcare programs.

7. Policy, Clinical, and Research Recommendations

7.1 Clinical Practice

  • Incorporate PFAS exposure assessment (through questionnaires or biomonitoring) into reproductive and menopause clinics.

  • Train healthcare providers to recognize environmental factors affecting hormone therapy outcomes.

  • Develop context-specific HT guidelines for women in high-exposure regions, particularly near contaminated water systems.

7.2 Public Health and Environmental Policy

  • Establish national PFAS monitoring programs targeting water sources, foods, and biological samples.

  • Enforce phase-outs or bans on PFAS-containing consumer and industrial products, prioritizing cosmetics and packaging.

  • Upgrade wastewater treatment infrastructure with PFAS removal technologies (e.g., activated carbon filtration, reverse osmosis).

  • Promote community-based water testing and awareness campaigns, especially for women relying on untreated surface water.

7.3 Gender-Responsive Environmental Governance

Policy responses should explicitly recognize women’s unique biological vulnerability and exposure pathways. Environmental laws should integrate gender health assessments, ensuring that chemical regulation aligns with reproductive and maternal health priorities.

7.4 Research and Surveillance

  • Fund longitudinal cohort studies exploring PFAS–HT interactions in African and Asian populations.

  • Develop biospecimen repositories for PFAS-exposure mapping.

  • Support interdisciplinary collaborations between environmental scientists, endocrinologists, and pharmacologists to refine HT protocols in polluted contexts.

8. Ethical and Socioeconomic Considerations

PFAS exposure intersects with social determinants of health, including poverty, occupation, and gender inequality. Women working in textile, food packaging, or informal waste sectors face occupational exposure in addition to environmental sources. Health systems must adopt a precautionary principle, prioritizing prevention over treatment and promoting environmental justice by ensuring access to clean water and safe consumer products.

9. Conclusion

PFAS pollution represents a silent but profound threat to women’s hormonal and reproductive health. Its capacity to alter the metabolism and efficacy of hormone therapies calls for immediate interdisciplinary attention. Protecting women from the dual burden of environmental contamination and therapeutic vulnerability requires coordinated policies spanning health, environment, and industry.
An integrated policy approach—combining environmental regulation, gender-sensitive health programming, and rigorous PFAS monitoring—will be pivotal in safeguarding women’s endocrine and reproductive health in both developed and developing contexts.

10. References

  • Sunderland, E. M., et al. (2019). A review of the pathways of human exposure to PFAS and health implications. Environmental Health Perspectives, 127(4), 45001.

  • Kim, S., et al. (2021). Associations between PFAS exposure and menopause-related hormone levels in women. Journal of Clinical Endocrinology & Metabolism, 106(8), e3224–e3235.

  • López-Díaz, C., et al. (2022). Endocrine disruption and PFAS exposure in women: Molecular mechanisms and clinical consequences. Toxicology Reports, 9, 1501–1513.

  • Grandjean, P., & Clapp, R. (2023). Perfluorinated compounds: Emerging insights into endocrine and metabolic effects. Environmental Research, 216, 114718.

  • UNEP & WHO (2024). Chemical Pollution and Women’s Health in Low- and Middle-Income Countries. Nairobi: United Nations Environment Programme.

Comments

Post a Comment

Popular posts from this blog

-
  Impacts of Pit Latrine Waste on Early Puberty in Africa Introduction Across sub-Saharan Africa, pit latrines serve as the primary sanitation infrastructure for over 50% of urban populations and an even higher proportion in rural areas, providing a low-cost solution to the challenge of open defecation. These simple, often unlined pits collect human waste but pose significant risks to environmental and public health due to potential groundwater contamination. Emerging evidence suggests that chemical pollutants from pit latrines, particularly endocrine-disrupting chemicals (EDCs), may contribute to early puberty in children, especially girls, with far-reaching health, social, and educational consequences. Early puberty, defined as pubertal development before age 8 in girls or 9 in boys, is associated with increased risks of mental health disorders, reproductive health issues, and socioeconomic challenges, particularly in resource-constrained settings. In Africa, where sanitation inf...
Read more
-
  Health insurance affordability and the quality of life among low Socioeconomic Status (SES) individuals in Low- and Middle-Income Countries (LMICs)   Preamble: Whereas the right to health is a fundamental human right, it remains inaccessible to many, especially those of low socioeconomic status (SES) in low- and middle-income countries (LMICs); and whereas the affordability of health insurance is a critical factor that can enhance or impede access to necessary healthcare services; we recognize that the ability to obtain health insurance plays a pivotal role in determining the quality of life for individuals and families within these communities. Acknowledging that the lack of affordable health insurance options leads to a disproportionate burden of disease and financial hardship on low SES populations; and understanding that the provision of affordable health insurance is not only a matter of social justice but also an investment in the social and economic development ...
Read more
-
Child Health:  Dealing with Aflatoxins in Children’s Food Aflatoxins, produced primarily by Aspergillus flavus and A. parasiticus , are highly toxic and carcinogenic mycotoxins that contaminate key food crops in tropical and subtropical regions. In low- and middle-income countries (LMICs), especially across sub-Saharan Africa, chronic exposure to aflatoxins in staple foods poses grave health risks for children, including growth impairment, immunosuppression, developmental deficits, and increased vulnerability to infectious diseases. This paper explores the sources of aflatoxin contamination in children's food, its public health impacts, and proposes multisectoral policies and interventions to protect child health and nutrition, with a focus on evidence from Africa. 1. Introduction Aflatoxin contamination is one of the most pressing yet under-addressed food safety challenges affecting children in LMICs. Staple foods such as maize, sorghum, groundnuts, and dairy products are pro...
Read more